Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by 201% year-on-year to $49.5 million is its superior efficacy compared to PPIs. Importantly, Takeda's vonoprazan sales also showed positive dynamics, increasing from 31.1 billion yen to 33.9 billion yen in Q2 2025. In this article, you'll learn why I continue to cover Phathom with a'Buy' rating. Klaus Vedfelt/DigitalVision via Getty Images In my article from October, "My Top 5 Biotech Stocks Big Pharma Could Buy Next," I mentioned how Phathom Pharmaceutical's ( PHAT ) Voquezna and Voquezna Triple Pak is actively capturing share in the U.S. GERD and H. pylori infection treatment markets. This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]Yahoo! Finance
- Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]Seeking Alpha
- Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
PHAT
Earnings
- 10/30/25 - Beat
PHAT
Sec Filings
- 1/15/26 - Form 4
- 1/8/26 - Form 8-K
- 1/8/26 - Form 424B5
- PHAT's page on the SEC website